PHusis Therapeutics

PHusis Therapeutics is a biotechnology company that develops precision medicines for the treatment of cancer. The company utilizes its proprietary computational modeling platform, PHuDock, to rapidly identify small molecule inhibitors that target proteins with regulatory pleckstrin homology (PH)-domains. By binding selectively to these domains, the company’s compounds aim to modulate protein signaling pathways that drive cancer growth and metastasis, offering a novel approach to therapeutic intervention.

This technology enables PHusis to identify and optimize drug leads more efficiently and cost-effectively. The company focuses on critical cancer targets, including PDK1 and mutant KRAS and NRAS, with the goal of providing targeted treatments based on a patient's specific mutational profile. This approach aims to improve clinical outcomes by focusing therapy on patients most likely to respond, while reducing unnecessary treatments. PHusis maintains a pipeline of drug candidates and has received support through federal grants and research incubator programs.